Myles Minter is ranked #534 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Myles Minter (William Blair) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Myles Minter's stock ratings?

About 65% of Myles's ratings were profitable over a one-year hold, with an average return of +13.8% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Myles Minter

Myles Minter

William Blair

Wall Street Analyst

★★★★☆

#534

on 13Foresight · ranked by our own returns

63%

Success Rate

+13.6%

Average Return

31 of 49 calls profitable · +9.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 63% of Myles Minter's ratings turned a profit when each position was held for 1 year — averaging +13.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

228 Buy 52 Hold 0 Sell

Myles's Stock Coverage 32 ratings · 2026-07-14

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
IONS Ionis Pharmaceuticals	Jul 09, 2026	BUY	Strong Buy +39.5% avg upside 43 analysts	—	-9.4%
VRTX Vertex Pharmaceuticals	Jul 07, 2026	BUY	Strong Buy -8.0% avg upside 61 analysts	—	-7.1%
ARCT Arcturus Therapeutics	Jul 02, 2026	BUY	Buy +330.3% avg upside 36 analysts	—	·
VTGN VistaGen Therapeutics	Jun 30, 2026	HOLD	Hold +928.0% avg upside 8 analysts	—	+13.0%
LRMR Larimar Therapeutics	Jun 29, 2026	BUY	Strong Buy +368.9% avg upside 22 analysts	—	+12.8%
MRNA Moderna	Jun 27, 2026	HOLD	Hold +3.4% avg upside 38 analysts	—	-2.1%
CAMP CAMP4 Therapeutics Corporation	Jun 25, 2026	BUY	Strong Buy +114.6% avg upside 9 analysts	—	+10.5%
ARGX Argenx Se	Jun 24, 2026	BUY	Strong Buy -14.1% avg upside 46 analysts	—	+2.9%
NTLA Intellia Therapeutics	Jun 15, 2026	BUY	Buy +193.2% avg upside 37 analysts	—	-4.7%
NMRA Neumora Therapeutics, Inc.	Jun 15, 2026	BUY	Buy +377.8% avg upside 11 analysts	—	+72.8%
SLN Silence Therapeutics	Jun 11, 2026	BUY	Buy +252.5% avg upside 10 analysts	—	·
DNTH Dianthus Therapeutics	Jun 10, 2026	BUY	Strong Buy -8.2% avg upside 29 analysts	—	+27.7%
AXSM Axsome Therapeutics	Jun 04, 2026	BUY	Strong Buy -3.2% avg upside 28 analysts	—	+1.0%
NBIX Neurocrine	Jun 02, 2026	BUY	Strong Buy +0.8% avg upside 37 analysts	—	+14.4%
BHVN Biohaven Ltd.	May 28, 2026	HOLD	Buy +50.1% avg upside 25 analysts	—	+51.9%
BBIO BridgeBio Pharma	May 27, 2026	BUY	Strong Buy +10.9% avg upside 34 analysts	—	+29.3%
DNLI Denali Therapeutics	May 22, 2026	BUY	Strong Buy +44.6% avg upside 24 analysts	—	+37.8%
BIIB Biogen	May 22, 2026	BUY	Strong Buy +19.7% avg upside 52 analysts	—	+2.8%
KRRO Korro Bio	May 18, 2026	BUY	Strong Buy +98.9% avg upside 19 analysts	—	+40.4%
ANRO Alto Neuroscience, Inc.	May 13, 2026	BUY	Strong Buy +10.6% avg upside 13 analysts	—	+14.1%
IMUX Immunic	May 13, 2026	BUY	Strong Buy +157.3% avg upside 21 analysts	—	+7.0%
OVID Ovid Therapeutics	May 12, 2026	BUY	Strong Buy +92.5% avg upside 17 analysts	—	-8.4%
ALEC Alector	May 08, 2026	HOLD	Hold +605.9% avg upside 14 analysts	—	-23.3%
XENE Xenon	May 08, 2026	BUY	Strong Buy -6.9% avg upside 28 analysts	$80.65 19.15% Upside	+12.3%
TRDA Entrada Therapeutics Inc	May 07, 2026	BUY	Strong Buy +214.6% avg upside 10 analysts	—	-3.6%
CTNM Contineum Therapeutics, Inc. Class A	May 06, 2026	BUY	Strong Buy +38.2% avg upside 8 analysts	$14.00 4.33% Downside	+1.7%
ALNY Alnylam Pharma	Apr 30, 2026	BUY	Strong Buy +19.8% avg upside 51 analysts	—	+17.3%
VERX Vertex	Mar 31, 2026	BUY	Buy +170.9% avg upside 23 analysts	—	+7.6%
OKUR OnKure Therapeutics	Dec 22, 2023	HOLD	Buy +491.9% avg upside 13 analysts	—	-38.4%
NEUP Neuphoria Therapeutics	Sep 28, 2023	BUY	Strong Buy +467.3% avg upside 6 analysts	—	-81.0%
PRAX Praxis Precision Medicines	Mar 03, 2023	HOLD	Strong Buy +67.2% avg upside 24 analysts	—	+231.4%
NERV Minerva Neurosciences	Dec 29, 2022	HOLD	Buy +69.1% avg upside 8 analysts	—	+307.3%

🔒 27 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Myles Minter — Frequently Asked Questions

How accurate are Myles Minter's stock ratings?

Based on the calls 13Foresight could measure, about 65% of Myles's ratings were profitable over a one-year hold, with an average return of +13.8% per rating, or +10.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Myles ranked on 13Foresight?

Myles Minter is currently ranked #534 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Myles cover?

Myles most recently has ratings on IONS, VRTX, ARCT, VTGN, LRMR, MRNA, CAMP, ARGX, NTLA, NMRA, SLN, DNTH and 20 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!